Dr. Chuanliang Cui is a prominent young expert in the fields of melanoma and genitourinary cancers in China. He has been deeply engaged in frontline clinical practice, focusing on the systemic treatment and translational research of melanoma, as well as renal cell carcinoma, bladder cancer, and urothelial carcinoma. In 2010, he conducted research and clinical training as a visiting scholar at the University of Pittsburgh Medical Center (UPMC), gaining exposure to advanced international treatment concepts and techniques.
Dr. Cui has extensive experience in immunotherapy, targeted therapy, and novel therapeutic approaches such as antibody–drug conjugates (ADCs). As a principal investigator, he has led and participated in multiple national key research projects and registration clinical trials of both international and domestic innovative anticancer drugs, contributing significantly to their clinical development and application in China. In addition, he has played an active role in drafting and updating several national clinical guidelines and expert consensus documents in oncology, helping to advance the standardization, scientific rigor, and forward-looking development of cancer care in China.
